Clinical Trials
4 trialsNCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting